11-12 September 2018 //  Lancaster Royal Hotel, London


Tu Diep

Tu Diep

Vice President of Operations , OncoSec

Tu Diep has more than 10 years of experience in scientific and clinical research. Prior to joining OncoSec, Mr. Diep was at Protox Therapeutics Inc., (now Sophiris  Bio Inc.), a company developing highly targeted, minimally invasive treatment for benign prostatic hyperplasia. During Mr. Diep’s 6 years at Protox, he held a number of positions of increasing responsibility where he gained extensive experience in preclinical research and development, clinical protocol development and design, clinical operations, and biologics manufacturing. Prior to leaving Protox, he was integrally involved in solidifying a $75 million regional partnership with the Japanese pharmaceutical company Kissei, as well as, securing a $35 million investment from the private equity firm, Warburg Pincus.

At OncoSec, Mr. Diep has held positions of increasing responsibility including Executive Director, Clinical Development, where he led the clinical research and operations for the Company. As VP of Operations, he oversees day-to-day operations and also leads the business development efforts at OncoSec. Mr. Diep holds a Master of Science in Physiology from the University of Toronto.


2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad